Top Markets
Coin of the day
Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.

CRXTQ
株式のランク #40849
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to... Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.
株価
$0.0014
最終同期: 2023-02-28
時価総額
$72.83K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Clarus Therapeutics Holdings, Inc. (CRXTQ)

カテゴリー

Clarus Therapeutics Holdings, Inc.(CRXTQ)のEPS
2026 時点のEPS TTM: 0
Clarus Therapeutics Holdings, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Clarus Therapeutics Holdings, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差
$29.85 -
US
$8.65 -
US
$3.55 -
US
$20.39 -
CH
$1.26 -
US